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BACKGROUND: The prognosis of patients with Dukes stage B colorectal cancer is unpredictable and there is continuing interest in
simply and reliably identifying patients at high risk of developing recurrence and dying of their disease. The aim of this study was to
devise a clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes stage B colorectal cancer.
METHODS: A total of 1350 patients who underwent surgery for Dukes stage B colorectal cancer between 1991 and 1994 in 11
hospitals in Scotland were included in the analysis.
RESULTS: On follow-up, 926 patients died of whom 479 died of their cancer. At 10 years, cancer-specific survival was 61% and overall
survival was 38%. On multivariate analysis, age X75 (hazard ratio (HR) 1.45, 95% confidence interval (CI) 1.15–1.82, P¼ 0.001),
emergency presentation (HR 1.59, 95% CI 1.27–1.99, Po0.001) and anastomotic leak (HR 2.17, 95% CI 1.24–3.78, Po0.01) were
independently associated with cancer-specific survival in colon cancer. On multivariate analysis, only age X75 (HR 1.58, 95% CI
1.14–2.18, Po0.01) was associated with cancer-specific survival in rectal cancer. Age, presentation and anastomotic leak hazards
could be simply added to form a clinical risk score from 0 to 2 in colon cancer. In patients with Dukes B stage colon cancer, the
cancer-specific survival at 5 years for patients with a cumulative score 0 was 81%, 1 was 67% and 2 was 63%. The cancer-specific
survival rate at 10 years for patients with a clinical risk score of 0 was 72%, 1 was 58% and 2 was 53%.
CONCLUSION: The results of this study, in a mature cohort, introduce a new simple clinical risk score for patients undergoing surgery
for Dukes B colon cancer. This provides a solid foundation for the examination of the impact of additional factors and treatment on
prediction of 3-, 5- and 10-year cancer-specific survival.
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Colorectal cancer is the second commonest cause of cancer death
in Western Europe and North America (Parkin et al, 2005). Many
patients have evidence of locally advanced or metastatic disease at
the time of initial presentation. Even in those undergoing
apparently curative resection for Dukes stage B disease, approxi-
mately one-third will die of their disease within 5 years (McArdle
and Hole, 2002; Morris et al, 2006). In view of these poor results,
there is increasing interest in the use of adjuvant chemotherapy in
these patients.
The treatment for Dukes B colorectal cancer remains primarily
based on surgery alone and adjuvant chemotherapy is not
routinely given. Conventionally, in these patients the decision
whether or not to offer adjuvant 5-fluorouracil-based chemo-
therapy is mainly based on the patient’s age and fitness to tolerate
chemotherapy. However, even in this selected cohort, the impact of
chemotherapy on outcome is unpredictable. Therefore, there is
continuing interest in simply and reliably identifying patients at
high risk of developing recurrence and dying of their disease
(Cascinu et al, 2003; Benson et al, 2004). The significance of this
problem is increasing with the widespread introduction of
screening programmes and the consequent increase in proportion
of patients presenting with early-stage disease (Benson, 2007).
On the basis of analysis of large data sets, there is reliable
information that a number of routinely collected factors influence
outcome following surgery for Dukes B colorectal cancer. These
include older age (Mulcahy et al, 1994; Shankar and Taylor, 1998;
McMillan et al, 2008), male gender (McArdle et al, 2003; Paulson
et al, 2009), socioeconomic deprivation (Hole and McArdle, 2002;
Kelsall et al, 2009), tumour site (McArdle and Hole, 2002),
emergency presentation (McArdle and Hole, 2004a; Wong et al,
2008), surgeon specialisation (McArdle and Hole, 2004b; Renzulli
et al, 2006) and anastomotic leakage (McArdle et al, 2005; Law
et al, 2007).
Therefore, the aim of this study was to devise a clinical risk
score to predict 3-, 5- and 10-year survival in patients undergoing
surgery for Dukes stage B colorectal cancer.
PATIENTS AND METHODS
A total of 1411 patients who underwent a resection for Dukes B
colorectal cancer between 1 January 1991 and 31 December 1994 in
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11 hospitals in the central belt of Scotland were included in the
study. Information was abstracted from case notes for different
patients by two specially trained data managers. Details included
age, sex, deprivation category (DEPCAT), site of tumour, Dukes’
stage, the nature of surgery, postoperative mortality and adjuvant
therapy. Data for 1991 and 1992 were collected retrospectively, and
those for 1993 and 1994 were collected prospectively. There was no
difference in baseline characteristics of the patients between the
two periods.
Cancer-specific deaths were determined as a first, or principal
underlying cause of death with International Classification of
Diseases (ICD) 9 codes for colon and rectal cancers, 153 and 154,
as well as 150, 157, 159, 199 and by ICD-10 codes C18 to 20, as well
as C15, C25, C26 and C80. Overall survival was determined as
deaths from any cause. Death records were complete until 28
September 2007 and this was therefore the censor date for all
individuals who had not died.
Patients’ socioeconomic circumstances were inferred using the
DEPCAT, a validated categorical score that ranks residential
postcodes from 1 (most affluent) to 7 (most deprived) using four
Census variables that were found to best predict health outcomes –
car ownership, unemployment, overcrowding and lower occupa-
tional social classes (IV and V) (Carstairs and Morris, 1991). They
were further grouped into three conventional categories: 1 and 2
(affluent); 3–5 (intermediate); and 6 and 7 (deprived).
Patients who were considered as an emergency had either
presented with significant blood loss, obstruction or perforation
(McArdle et al, 2006). Tumours were classified according to site,
colon or rectum. The extent of tumour spread was assessed by
conventional Dukes’ classification based on histological examina-
tion of the resected specimen. Patients were deemed to have had a
curative resection if the surgeon considered that there was no
macroscopic residual tumour once resection had been completed.
Individual surgeons were defined as specialists or non-specialists
by a panel of six senior consultants and one of the authors
(CSMcA). These assessments were made without the knowledge of
the outcome and before any analysis was performed.
Approval was obtained for information on date and cause of
death to be checked with that received by the cancer registration
system through linkage with the Registrar General (Scotland).
Deaths up to 28 September 2007 have been included in the
analysis, providing a median follow-up time of 14.6 years
(minimum 13 years, maximum 17 years).
Statistical analysis
The grouping of variables was carried out using conventional
categories. Univariate and multivariate survival analysis and
calculation of hazard ratios (HRs) were carried out using Cox’s
proportional hazards model. The proportionality assumption was
tested by visual inspection of log-minus-log plots. Interactions
between variables in the multivariate analyses were tested by the
addition of all possible pairwise interaction terms. Cumulative
survival following colorectal cancer surgery was estimated using
the Kaplan–Meier method and the log-rank used to test for
independence between variables. Predictive model analysis using
receiver operating characteristic analysis was carried out.
C-statistics were calculated with the null hypothesis that the true
area under the curve was 0.5, and asymptotic 95% confidence
intervals (CIs) calculated around the best estimate. Analysis was
performed using the SPSS software package version 15.0 (SPSS
Inc., Chicago, IL, USA).
RESULTS
Of the 1411 patients who underwent a resection for Dukes B
colorectal cancer, there were 61 postoperative deaths and 1350
patients were included in the analysis. The majority were aged
o75 years (64%), were not socioeconomically deprived (80%),
presented electively (71%), had colonic tumours (68%) and were
treated by a general surgeon (74%). A total of 45 (3%) patients
developed an anastomotic leak and 36 (3%) patients received
adjuvant therapy. On follow-up, 926 patients died of whom 479
died of their cancer. At 10 years, cancer-specific survival was 61%
and overall survival was 38%, giving median survival times of 10.0
and 6.3 years, respectively.
The relationship between clinicopathological characteristics and
cancer-specific survival in patients with colon cancer is shown in
Table 1. On univariate analysis, age (Po0.01), mode of presenta-
tion (Po0.001) and anastomotic leak (Po0.01) were significantly
associated with cancer-specific survival. On multivariate analysis
of these significant factors, age X75 (HR 1.45, 95% CI 1.15–1.82,
P¼ 0.001), emergency presentation (HR 1.59, 95% CI 1.27–1.99,
Po0.001) and anastomotic leak (HR 2.17, 95% CI 1.24–3.78,
Po0.01) were independently associated with cancer-specific
survival (Table 1). There were no significant interactions between
any combination of age, presentation and anastomotic leak in the
colon model.
The relationship between clinicopathological characteristics
and cancer-specific survival in patients with rectal cancer is
shown in Table 2. On univariate analysis, age (Po0.01) and mode
of presentation (Po0.05) were significantly associated with
cancer-specific survival. On multivariate analysis of these
significant factors, only age X75 (HR 1.58, 95% CI 1.14–2.18,
Po0.01) was independently associated with cancer-specific
survival (Table 2).
The relationship between clinicopathological characteristics and
overall survival in patients with colon cancer is shown in Table 3.
On univariate analysis, age (Po0.001), sex (Po0.01) and mode of
presentation (Po0.001) were significantly associated with overall
Table 1 The relationship between clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for Dukes B colon cancer:
univariate and multivariate analysis
Univariate analysis Multivariate analysis
Risk factor Patients (n¼ 920) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (o75/X75 years) 562/358 1.43 (1.14–1.79) 0.002 1.45 (1.15–1.82) 0.001
Sex (female/male) 493/427 1.22 (0.98–1.53) 0.081
Deprivationa (intermediate) 164/589/166 1.15 (0.85–1.57) 0.369
(deprived) 1.06 (0.72–1.56) 0.780
Mode of presentation (elective/emergency) 592/328 1.58 (1.26–1.98) o0.001 1.59 (1.27–1.99) o0.001
Specialisation (yes/no) 197/700 1.19 (0.89–1.59) 0.241
Anastomotic leak (no/yes) 896/24 2.11 (1.21–3.67) 0.009 2.17 (1.24–3.78) 0.006
Adjuvant therapy (no/yes) 811/14 0.76 (0.28–2.03) 0.577
Abbreviation: CI¼ confidence interval. aBaseline – affluent. Baseline variables/comparison group in brackets after risk factor.
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survival. On multivariate analysis of these significant factors, age
X75 (HR 2.15, 95% CI 1.84–2.52, Po0.001), sex (HR 1.30, 95% CI
1.11–1.52, P¼ 0.001) and emergency presentation (HR 1.44, 95%
CI 1.22–1.69, Po0.001) were independently associated with
overall survival (Table 3). There were no significant interactions
between any combination of age, presentation and anastomotic
leak in the colon model.
The relationship between clinicopathological characteristics and
overall survival in patients with rectal cancer is shown in Table 4.
On univariate analysis, age (Po0.001) and mode of presentation
(Po0.10) were significantly associated with overall survival.
However, on multivariate analysis of these significant factors,
only age X75 (HR 2.20, 95% CI 1.74–2.79, Po0.001) was
independently associated with overall survival (Table 4).
With reference to cancer-specific survival in colon cancer, as the
magnitude of the covariates of age X75 (1.45), emergency
presentation (1.59) and anastomotic leak (2.17) were similar, they
could be allocated a score of 1 if they occurred or 0 if absent.
Together these factors could be simply added to form a clinical risk
score from 0 to 3. From the Kaplan–Meier curve of this clinical
risk score it appeared that there was overlap in cancer-specific
survival between clinical risk scores 2 and 3 and therefore these
were combined to give clinical risk scores of 0, 1 and 2. The
relationship between such a cumulative prognostic score and
3-, 5- and 10-year cancer-specific survival is shown in Figure 1.
In patients with Dukes B stage colon cancer, the cancer-specific
survival rates at 3 years for patients with a cumulative score 0 was
87%, 1 was 75% and 2 was 67% (Table 5). The cancer-specific
Table 2 The relationship between clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for Dukes B rectal cancer:
univariate and multivariate analysis
Univariate analysis Multivariate analysis
Risk factor Patients (n¼ 430) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (o75/X75 years) 302/128 1.65 (1.19–2.27) 0.002 1.58 (1.14–2.18) 0.006
Sex (female/male) 186/244 1.18 (0.87–1.60) 0.298
Deprivationa (intermediate) 65/260/105 0.95 (0.63–1.45) 0.812
(deprived) 0.93 (0.58–1.50) 0.767
Mode of presentation (elective/emergency) 364/66 1.56 (1.06–2.28) 0.023 1.44 (0.98–2.12) 0.062
Specialisation (yes/no) 122/299 1.09 (0.77–1.53) 0.625
Anastomotic leak (no/yes) 409/21 1.25 (0.66–2.37) 0.495
Adjuvant therapy (no/yes) 348/22 1.62 (0.88–3.01) 0.124
Abbreviation: CI¼ confidence interval. aBaseline – affluent. Baseline variables/comparison group in brackets after risk factor.
Table 3 The relationship between clinicopathological characteristics and overall survival in patients undergoing surgery for Dukes B colon cancer:
univariate and multivariate analysis
Univariate analysis Multivariate analysis
Patients (n¼ 920) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (o75/X75 years) 562/358 2.13 (1.81–2.49) o0.001 2.15 (1.84–2.52) o0.001
Sex (female/male) 493/427 1.26 (1.07–1.47) 0.005 1.30 (1.11–1.52) 0.001
Deprivationa (intermediate) 164/589/166 1.22 (0.97–1.52) 0.089
(deprived) 1.28 (0.98–1.67) 0.076
Mode of presentation (elective/emergency) 592/328 1.41 (1.20–1.65) o0.001 1.44 (1.22–1.69) o0.001
Specialisation (yes/no) 197/700 0.92 (0.76–1.11) 0.362
Anastomotic leak (no/yes) 896/24 1.56 (0.99–2.46) 0.057
Adjuvant therapy (no/yes) 811/14 0.48 (0.22–1.08) 0.077
Abbreviation: CI¼ confidence interval. aBaseline – affluent. Baseline variables/comparison group in brackets after risk factor.
Table 4 The relationship between clinicopathological characteristics and overall survival in patients undergoing surgery for Dukes B rectal cancer:
univariate and multivariate analysis
Univariate analysis Multivariate analysis
Patients (n¼ 430) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (o75/X75 years) 302/128 2.26 (1.78–2.85) o0.001 2.20 (1.74–2.79) o0.001
Sex (female/male) 186/244 1.12 (0.89–1.41) 0.324
Deprivationa (intermediate) 65/260/105 1.18 (0.84–1.64) 0.345
(deprived) 1.22 (0.84–1.77) 0.300
Mode of presentation (elective/emergency) 364/66 1.47 (1.09–1.97) 0.011 1.30 (0.97–1.75) 0.084
Specialisation (yes/no) 122/299 1.04 (0.80–1.34) 0.779
Anastomotic leak (no/yes) 409/21 1.08 (0.64–1.81) 0.777
Adjuvant therapy (no/yes) 348/22 1.16 (0.69–1.95) 0.589
Abbreviation: CI¼ confidence interval. aBaseline – affluent. Baseline variables/comparison group in brackets after risk factor.
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survival rates at 5 years for patients with a cumulative score 0 was
81%, 1 was 67% and 2 was 63%. The cancer-specific survival rates
at 10 years for patients with a cumulative score 0 was 72%, 1 was
58% and 2 was 53%. The area under the curve for the clinical risk
score with cancer mortality as an end point at 3, 5 and 10 years was
(0.603, 95% CI 0.559–0.648, Po0.001), (0.582, 95% CI 0.541–
0.623, Po0.001) and (0.561, 95% CI 0.522–0.600, P¼ 0.003),
respectively.
DISCUSSION
The results of this study show that in a large mature cohort of
patients undergoing resection for Dukes B colon and rectal cancer,
there were a number of clinical factors that were associated with
poorer cancer-specific survival. In colon cancer age, mode of
presentation and anastomotic leak were independently associated
with cancer-specific survival. In rectal cancer, only advanced age
was independently associated with cancer-specific survival. The
reliable identification of these factors enabled the formation of a
simple clinical risk score for colon cancer that clearly identified
differences in 3-, 5- and 10-year cancer-specific survival.
It was of interest that this simple clinical risk score identified
variations in 5-year cancer-specific survival of between 81 and 63%
in patients with Dukes B colon cancer. These results have a
number of important implications. First, simple nomograms from
the present paper can help clinicians to readily identify those
patients at higher risk of developing recurrence and dying of their
disease. Second, these scores provide simple stratification factors
for clinical studies and trials. Third, the score may provide a basis
for future staging systems for Dukes B colorectal cancer to which
further discriminatory variables might be added.
In this study, because of its potential impact on clinical practice,
the main focus was on the factors that were independently
associated with cancer-specific survival. However, it was of interest
that, on 10-year follow-up, almost as many patients died of
intercurrent disease (n¼ 447) as died of their cancer (n¼ 479).
Given that many registries in different countries report the date of
death, but not the cause of death, it was of interest that the
significant independent factors in this study, age and mode of
presentation, were similarly associated with overall survival.
In this study, a number of more recently recognised tumour
prognostic factors such as intra or extramural vascular invasion,
peritoneal involvement, margin involvement and tumour perfora-
tion (Roxburgh et al, 2009) were not available for analysis. Also,
recent web-based prognostic calculators developed to individualise
decisions regarding adjuvant therapy in patients with pathological
TNM stage II and III colon cancer (Bardia et al, 2010), have
included T stage and tumour grade (Numeracy, www.mayoclinic.
com/calcs) and comorbidity and the number of examined lymph
nodes (Adjuvant!, www.adjuvantonline.com). These were not
available in the present analysis. Since very few patients in this
study received either adjuvant (o3%) or neoadjuvant therapy
(0%), the effect of therapy in colon and rectal cancer could not be
examined. Furthermore, new approaches to staging the host
inflammatory response, such as the Glasgow Prognostic Score
(McMillan, 2009; Roxburgh and McMillan, 2010) were not
available in the present analysis. Nevertheless, the present clinical
risk score in a mature cohort provides a solid foundation for the
examination of the impact of these additional factors and
treatment on prediction of 3-, 5- and 10-year cancer-specific
survival in patients undergoing surgery for Dukes B colon cancer.
It may be hypothesised that the effects of age, mode of
presentation and anastomotic leak on cancer-specific survival are
biologically mediated and therefore likely to be generalisable to
other tumour types. In this study, mode of presentation and
anastomotic leak were not significantly independently associated
with cancer-specific survival in rectal cancer. However, the
number of rectal cancers was less than half that of the colon
cancers and less than 500. It is of interest that a number of recent
reports, in larger cohorts, indicate that postoperative anastomotic
leakage (Ptok et al, 2007; Sierzega et al, 2010) is also associated
with poor long-term survival, independent of tumour staging, in
rectal and gastric cancer. Therefore, aspects of the present simple
clinical risk score, for patients with Dukes stage B colon cancer,
may be useful in patients undergoing surgery for other gastro-
intestinal cancers.
In summary, the results of this study, in a mature cohort,
introduce a new simple clinical risk score for patients undergoing
surgery for Dukes B colon cancer. This provides a solid foundation
for the examination of the impact of additional factors and
treatment on prediction of 3-, 5- and 10-year cancer-specific
survival.
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Figure 1 The relationship between a clinical risk score (0, 1 and 2 from
top to bottom) and cancer-specific survival in patients undergoing surgery
for Dukes B colon cancer.
Table 5 The relationship between a clinical risk score and cancer-specific survival in patients undergoing surgery for colon cancer
Dukes B Hazard ratio
Cancer-specific survival rate, % (SE)
n¼920 (%) (95% CI) P-value 3 year 5 year 10 year
Clinical risk score 0 355 (39) 1 87 (2) 81 (2) 72 (3)
Clinical risk score 1 425 (46) 1.80 (1.39–2.32) o0.001 75 (2) 67 (2) 58 (3)
Clinical risk score 2 140 (15) 2.31 (1.64–3.26) o0.001 67 (4) 63 (5) 53 (5)
Abbreviations: CI¼ confidence interval; SE¼ standard error.
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